Loading...

Eurobio Scientific

ENXTPA:ALERS
Snowflake Description

Adequate balance sheet with reasonable growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ALERS
ENXTPA
€36M
Market Cap
  1. Home
  2. FR
  3. Pharmaceuticals & Biotech
Company description

Eurobio Scientific discovers and commercializes specialty diagnostic products in the areas of transplantation, infectious diseases, life-science, and cancer. The last earnings update was 53 days ago. More info.


Add to Portfolio Compare Print
ALERS Share Price and Events
7 Day Returns
0.9%
ENXTPA:ALERS
-2.6%
FR Biotechs
2.4%
FR Market
1 Year Returns
-32.7%
ENXTPA:ALERS
-37.5%
FR Biotechs
2.1%
FR Market
ALERS Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Eurobio Scientific (ALERS) 0.9% -2.6% 4.7% -32.7% -53.8% -77.5%
FR Biotechs -2.6% -8.1% -9% -37.5% -48.3% -46.3%
FR Market 2.4% 3.5% 4.8% 2.1% 39.7% 33.6%
1 Year Return vs Industry and Market
  • ALERS outperformed the Biotechs industry which returned -37.5% over the past year.
  • ALERS underperformed the Market in France which returned 2.1% over the past year.
Price Volatility
ALERS
Industry
5yr Volatility vs Market
Related Companies

ALERS Value

 Is Eurobio Scientific undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Eurobio Scientific to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Eurobio Scientific.

ENXTPA:ALERS Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 11.3%
Perpetual Growth Rate 10-Year FR Government Bond Rate 0.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for ENXTPA:ALERS
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year FR Govt Bond Rate 0.7%
Equity Risk Premium S&P Global 6.7%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.32
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.325 (1 + (1- 33%) (63.53%))
1.595
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.6
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.73% + (1.595 * 6.65%)
11.34%

Discounted Cash Flow Calculation for ENXTPA:ALERS using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Eurobio Scientific is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

ENXTPA:ALERS DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 11.34%)
2019 -1.00 Analyst x1 -0.90
2020 3.60 Analyst x1 2.90
2021 5.04 Est @ 40.07% 3.65
2022 6.47 Est @ 28.27% 4.21
2023 7.76 Est @ 20.01% 4.54
2024 8.87 Est @ 14.22% 4.65
2025 9.77 Est @ 10.18% 4.60
2026 10.49 Est @ 7.34% 4.44
2027 11.05 Est @ 5.36% 4.20
2028 11.49 Est @ 3.97% 3.92
Present value of next 10 years cash flows €36.22
ENXTPA:ALERS DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= €11.49 × (1 + 0.73%) ÷ (11.34% – 0.73%)
€109.06
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €109.06 ÷ (1 + 11.34%)10
€37.24
ENXTPA:ALERS Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €36.22 + €37.24
€73.47
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €73.47 / 10.90
€6.74
ENXTPA:ALERS Discount to Share Price
Calculation Result
Value per share (EUR) From above. €6.74
Current discount Discount to share price of €3.33
= -1 x (€3.33 - €6.74) / €6.74
50.6%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Eurobio Scientific is available for.
Intrinsic value
>50%
Share price is €3.33 vs Future cash flow value of €6.74
Current Discount Checks
For Eurobio Scientific to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Eurobio Scientific's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Eurobio Scientific's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Eurobio Scientific's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Eurobio Scientific's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ENXTPA:ALERS PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in EUR €-0.28
ENXTPA:ALERS Share Price ** ENXTPA (2019-06-24) in EUR €3.33
France Biotechs Industry PE Ratio Median Figure of 8 Publicly-Listed Biotechs Companies 18.9x
France Market PE Ratio Median Figure of 421 Publicly-Listed Companies 17.89x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Eurobio Scientific.

ENXTPA:ALERS PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTPA:ALERS Share Price ÷ EPS (both in EUR)

= 3.33 ÷ -0.28

-11.79x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Eurobio Scientific is loss making, we can't compare its value to the FR Biotechs industry average.
  • Eurobio Scientific is loss making, we can't compare the value of its earnings to the France market.
Price based on expected Growth
Does Eurobio Scientific's expected growth come at a high price?
Raw Data
ENXTPA:ALERS PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -11.79x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
110.5%per year
France Biotechs Industry PEG Ratio Median Figure of 7 Publicly-Listed Biotechs Companies -0.26x
France Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.55x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Eurobio Scientific, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Eurobio Scientific's assets?
Raw Data
ENXTPA:ALERS PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in EUR €3.00
ENXTPA:ALERS Share Price * ENXTPA (2019-06-24) in EUR €3.33
France Biotechs Industry PB Ratio Median Figure of 33 Publicly-Listed Biotechs Companies 2.27x
France Market PB Ratio Median Figure of 622 Publicly-Listed Companies 1.45x
ENXTPA:ALERS PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTPA:ALERS Share Price ÷ Book Value per Share (both in EUR)

= 3.33 ÷ 3.00

1.11x

* Primary Listing of Eurobio Scientific.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Eurobio Scientific is good value based on assets compared to the FR Biotechs industry average.
X
Value checks
We assess Eurobio Scientific's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Eurobio Scientific has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

ALERS Future Performance

 How is Eurobio Scientific expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
110.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Eurobio Scientific expected to grow at an attractive rate?
  • Eurobio Scientific's earnings growth is expected to exceed the low risk savings rate of 0.7%.
Growth vs Market Checks
  • Eurobio Scientific's earnings growth is expected to exceed the France market average.
  • Eurobio Scientific's revenue growth is expected to exceed the France market average.
Annual Growth Rates Comparison
Raw Data
ENXTPA:ALERS Future Growth Rates Data Sources
Data Point Source Value (per year)
ENXTPA:ALERS Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 110.5%
ENXTPA:ALERS Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 7.5%
France Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 27%
France Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 36.1%
France Market Earnings Growth Rate Market Cap Weighted Average 12.8%
France Market Revenue Growth Rate Market Cap Weighted Average 4.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ENXTPA:ALERS Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ENXTPA:ALERS Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-12-31 59 1 1
2019-12-31 55 -1 1
ENXTPA:ALERS Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-12-31 51 -1 -3
2018-09-30 50 0 -4
2018-06-30 48 1 -6
2018-03-31 46 2 -8
2017-12-31 43 2 -10
2017-09-30 38 0 -9
2017-06-30 32 -2 -9
2017-03-31 30 -2 -8
2016-12-31 28 -3 -8
2016-09-30 28 -8
2016-06-30 29 -4 -8
2016-03-31 29 -3 -7

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Eurobio Scientific's earnings are expected to grow significantly at over 20% yearly.
  • Eurobio Scientific's revenue is expected to grow by 7.5% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ENXTPA:ALERS Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Eurobio Scientific Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ENXTPA:ALERS Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-12-31
2019-12-31
ENXTPA:ALERS Past Financials Data
Date (Data in EUR Millions) EPS *
2018-12-31 -0.28
2018-09-30 -0.44
2018-06-30 -0.59
2018-03-31 -0.85
2017-12-31 -1.14
2017-09-30 -1.30
2017-06-30 -1.55
2017-03-31 -1.72
2016-12-31 -1.98
2016-09-30 -2.00
2016-06-30 -2.02
2016-03-31 -1.84

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Eurobio Scientific will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Eurobio Scientific's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the France market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the France market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Eurobio Scientific has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

ALERS Past Performance

  How has Eurobio Scientific performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Eurobio Scientific's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Eurobio Scientific does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Eurobio Scientific's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Eurobio Scientific's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Eurobio Scientific's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Eurobio Scientific Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ENXTPA:ALERS Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 51.07 -2.77 15.96
2018-09-30 49.68 -4.33 16.51
2018-06-30 48.29 -5.90 17.06
2018-03-31 45.54 -7.93 16.99
2017-12-31 42.78 -9.97 16.93
2017-09-30 37.55 -9.38 15.15
2017-06-30 32.32 -8.79 13.37
2017-03-31 30.07 -8.26 12.94
2016-12-31 27.83 -7.73 12.50
2016-09-30 28.33 -7.63 12.66
2016-06-30 28.84 -7.52 12.82
2016-03-31 29.31 -6.70 12.98
2015-12-31 29.78 -5.88 13.14
2015-09-30 30.33 -5.85 13.89
2015-06-30 30.88 -5.82 14.63
2015-03-31 30.96 -5.65 14.33
2014-12-31 31.04 -5.49 14.03
2014-09-30 31.26 -5.35 13.94
2014-06-30 31.47 -5.21 13.84
2014-03-31 31.34 -5.60 14.14
2013-12-31 31.22 -5.99 14.43
2013-09-30 25.09 -5.68 11.65
2013-06-30 18.97 -5.36 8.88
2013-03-31 12.18 -5.57 6.65
2012-12-31 5.39 -5.77 4.43
2012-09-30 5.13 -5.70 4.65
2012-06-30 4.87 -5.63 4.86

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Eurobio Scientific has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Eurobio Scientific has efficiently used its assets last year compared to the FR Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Eurobio Scientific improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Eurobio Scientific's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Eurobio Scientific has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

ALERS Health

 How is Eurobio Scientific's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Eurobio Scientific's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Eurobio Scientific is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Eurobio Scientific's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Eurobio Scientific's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Eurobio Scientific Company Filings, last reported 5 months ago.

ENXTPA:ALERS Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 29.62 20.01 11.01
2018-09-30 29.62 20.01 11.01
2018-06-30 31.41 17.28 6.85
2018-03-31 31.41 17.28 6.85
2017-12-31 31.69 17.65 11.79
2017-09-30 31.69 17.65 11.79
2017-06-30 35.97 16.31 11.48
2017-03-31 35.97 16.31 11.48
2016-12-31 12.23 5.86 7.91
2016-09-30 12.23 5.86 7.91
2016-06-30 19.32 1.05 7.34
2016-03-31 19.32 1.05 7.34
2015-12-31 23.31 0.90 11.69
2015-09-30 23.31 0.90 11.69
2015-06-30 26.00 1.14 11.61
2015-03-31 26.00 1.14 11.61
2014-12-31 27.95 1.40 14.13
2014-09-30 27.95 1.40 14.13
2014-06-30 31.13 1.65 14.66
2014-03-31 31.13 1.65 14.66
2013-12-31 20.56 1.91 5.69
2013-09-30 20.56 1.91 5.69
2013-06-30 23.12 2.13 5.91
2013-03-31 23.12 2.13 5.91
2012-12-31 24.50 2.33 9.80
2012-09-30 24.50 2.33 9.80
2012-06-30 10.91 0.64 11.22
  • Eurobio Scientific's level of debt (77.8%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (10.5% vs 77.8% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Eurobio Scientific has sufficient cash runway for more than 3 years based on current free cash flow.
  • Eurobio Scientific has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -12.2% each year.
X
Financial health checks
We assess Eurobio Scientific's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Eurobio Scientific has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

ALERS Dividends

 What is Eurobio Scientific's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Eurobio Scientific dividends.
If you bought €2,000 of Eurobio Scientific shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Eurobio Scientific's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Eurobio Scientific's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ENXTPA:ALERS Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.8%
France Market Average Dividend Yield Market Cap Weighted Average of 322 Stocks 3%
France Minimum Threshold Dividend Yield 10th Percentile 0.9%
France Bottom 25% Dividend Yield 25th Percentile 1.6%
France Top 25% Dividend Yield 75th Percentile 4.4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ENXTPA:ALERS Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Eurobio Scientific has not reported any payouts.
  • Unable to verify if Eurobio Scientific's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Eurobio Scientific's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Eurobio Scientific has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Eurobio Scientific's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Eurobio Scientific afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Eurobio Scientific has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

ALERS Management

 What is the CEO of Eurobio Scientific's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jean-Michel Grandmougin
TENURE AS CEO 1.1 years
CEO Bio

Mr. Jean-Michel Carle Grandmougin is President of the Management Board at Diaxonhit since May 2018. As President of DIAXONHIT's Management Board since June 2017, Jean-Michel Carle Grandmougin is in charge of the group's marketing and sales strategy, quality and regulatory issues, as well as sales in France. Jean-Michel Carle Grandmougin has more than 32 years of experience in the field of in vitro diagnostics and research in life sciences. Before becoming a member of the Management Board of the DIAXONHIT Group, he was Chairman and Chief Executive Officer and one of the two partners of the EUROBIO / Capforce Group which was acquired by DIAXONHIT in March 2017. He joined EUROBIO SA in 2006 as Sales Manager and quickly became its Managing Director. In June 2010, he acquired the company with Denis Fortier and the OTC Asset Management fund which sold back its shares in 2014 to Jean-Michel and Denis. In 1992, he joined BMD (now Theradiag) where he was Sales Director for 13 years before taking responsibility of its German activity. Holder of a bachelor's degree in biology, he began his career in 1985 at Technicon (now Bayer Diagnostics) as a Technical Sales Engineer to become Sales Manager at 30. Jean-Michel Carle Grandmougin owns approximately 17% of DIAXONHIT.

CEO Compensation
  • Insufficient data for Jean-Michel to compare compensation growth.
  • Insufficient data for Jean-Michel to establish whether their remuneration is reasonable compared to companies of similar size in France.
Management Team Tenure

Average tenure of the Eurobio Scientific management team in years:

3.4
Average Tenure
  • The tenure for the Eurobio Scientific management team is about average.
Management Team

Herve de Lamotte

TITLE
CFO & Member of the Management Board
COMPENSATION
€284K
AGE
59
TENURE
9.6 yrs

Jean-Michel Grandmougin

TITLE
President of the Management Board
TENURE
1.1 yrs

Denis Fortier

TITLE
GM & Member of the Management Board
TENURE
1.1 yrs

Jacques Martin

TITLE
Vice President of Marketing

Thomas Iff

TITLE
Chief Business Officer
TENURE
5.8 yrs
Board of Directors

Jean-Pierre Hermet

TITLE
Chairman of Supervisory Board

Pierre Chambon

TITLE
Chairman of Scientific Advisory Board

Dominique Stehelin

TITLE
Member of Scientific Advisory Board

Edwin Milgrom

TITLE
Member of Scientific Advisory Board

Michel Picot

TITLE
Member of Supervisory Board
COMPENSATION
€24K

Pierre Corvol

TITLE
Member of Scientific Advisory Board

Pascale Briand

TITLE
Member of Scientific Advisory Board

Gustavo Roman

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Eurobio Scientific's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Eurobio Scientific has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

ALERS News

Simply Wall St News

Is Eurobio Scientific's (EPA:ALERS) Balance Sheet A Threat To Its Future?

Does ALERS Produce Much Cash Relative To Its Debt? … Looking at ALERS’s €24m in current liabilities, the company has maintained a safe level of current assets to meet its obligations, with the current ratio last standing at 1.34x. … Next Steps: Although ALERS’s debt level is towards the higher end of the spectrum, its cash flow coverage seems adequate to meet obligations which means its debt is being efficiently utilised.

Simply Wall St -

Can We See Significant Insider Ownership On The Eurobio Scientific (EPA:ALERS) Share Register?

The big shareholder groups in Eurobio Scientific (EPA:ALERS) have power over the company. … As Nassim Nicholas Taleb said, 'Don’t tell me what you think, tell me what you have in your portfolio.'. … Eurobio Scientific is not a large company by global standards.

Simply Wall St -

How Does Investing In Eurobio Scientific (EPA:ALERS) Impact The Volatility Of Your Portfolio?

If you're interested in Eurobio Scientific (EPA:ALERS), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility).

Simply Wall St -

Those Who Purchased Eurobio Scientific Shares Five Years Ago Have A 83% Loss To Show For It

Imagine if you held Eurobio Scientific (EPA:ALERS) for half a decade as the share price tanked 83%. … Given that Eurobio Scientific didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. … In the last half decade, Eurobio Scientific saw its revenue increase by 9.5% per year.

Simply Wall St -

Is Eurobio Scientific (EPA:ALERS) Expensive For A Reason? A Look At The Intrinsic Value

In this article I am going to calculate the intrinsic value of Eurobio Scientific (EPA:ALERS). … by projecting its future cash flows and then discounting them to today's value. … Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model.

Simply Wall St -

Could Eurobio Scientific's (EPA:ALERS) Investor Composition Influence The Stock Price?

Every investor in Eurobio Scientific (EPA:ALERS) should be aware of the most powerful shareholder groups. … So it's nice to see some insider ownership, because it may suggest that management is owner-oriented. … Eurobio Scientific is a smaller company with a market capitalization of €30m, so it may still be flying under the radar of many institutional investors.

Simply Wall St -

Eurobio Scientific (EPA:ALERS) Is Expected To Breakeven

With the latest financial year loss of -€10.0m and a trailing-twelve month of -€5.9m, the €37m market-cap alleviates its loss by moving closer towards its target of breakeven? … In this article, I will touch on the expectations for ALERS’s growth and when analysts expect the company to become profitable … View our latest analysis for Eurobio Scientific

Simply Wall St -

Does Eurobio Scientific (EPA:ALERS) Have A Volatile Share Price?

Beta is a widely used metric to measure a stock's exposure to market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market. … In comparison a stock with a beta of over one tends to be move in a similar direction to the market in the long term, but with greater changes in price.

Simply Wall St -

Intrinsic Calculation For Eurobio Scientific (EPA:ALERS) Shows Investors Are Overpaying

Today I will be providing a simple run through of a valuation method used to estimate the attractiveness of Eurobio Scientific (EPA:ALERS) as an investment opportunity. … by estimating the company's future cash flows and discounting them to their present value. … discounted cash flows (DCF).

Simply Wall St -

Eurobio Scientific's (EPA:ALERS) Shift From Loss To Profit

The €48.62m market-cap company announced a latest loss of -€9.97m on 31 December 2017 for its most recent financial year result. … Many investors are wondering the rate at which ALERS will turn a profit, with the big question being “when will the company breakeven?” … Check out our latest analysis for Eurobio Scientific

Simply Wall St -

ALERS Company Info

Description

Eurobio Scientific discovers and commercializes specialty diagnostic products in the areas of transplantation, infectious diseases, life-science, and cancer. The company offers Tetanus Quick Stick, a test that is used in emergency clinics for the determination of the tetanus vaccination status of a patient; and commercializes cell culture media, molecular biology reagents, and proprietary antibodies. Its in-house development products include the BJI InoPlex, a multiplex serological test used for the diagnosis of prosthetic joint infections; and licensed products comprise AlloMap, a molecular test for the surveillance of heart-transplant patients in Europe. The company was formerly known as Diaxonhit and changed its name to Eurobio Scientific in June 2018. Eurobio Scientific was founded in 1997 and is headquartered in Paris, France.

Details
Name: Eurobio Scientific
ALERS
Exchange: ENXTPA
Founded: 1997
€36,296,620
10,899,886
Website: http://www.diaxonhit.com
Address: Eurobio Scientific
65 Boulevard Masséna,
Paris,
Ile-de-France, 75013,
France
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTPA ALERS Ordinary Shares Euronext Paris FR EUR 22. Nov 2005
Number of employees
Current staff
Staff numbers
128
Eurobio Scientific employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/24 21:02
End of day share price update: 2019/06/24 00:00
Last estimates confirmation: 2019/06/12
Last earnings filing: 2019/05/02
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.